GSK and Theravance initiate Phase III trial of COPD combination drug FF/VI

GlaxoSmithKline (GSK) and Theravance have initiated a Phase III trial of a combination treatment of the inhaled corticosteroid (ICS), fluticasone furoate and long-acting beta2agonist (LABA), vilanterol (FF/VI) in patients with chronic obstructive pul…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news